Ocera Therapeutics (OCRX) Misses Q4 EPS by 1c

Ocera Therapeutics (NASDAQ: OCRX) reported Q4 EPS of ($0.34), $0.01 worse than the analyst estimate of ($0.33). Revenue for the quarter came in at $24 thousand versus the consensus estimate of $10 thousand.

For earnings history and earnings-related data on Ocera Therapeutics (OCRX) click here.

You May Also Be Interested In

• Gogoro Inc (GGR) Reports Q2 Loss of $0.24, Offers FY26 Revenue Guidance
• X Financial (XYF) Tops Q2 EPS by 438c
• Martin Marietta completes acquisition of Lhoist North America